Literature DB >> 17121713

[Expressions of RhoC and osteopontin in esophageal squamous carcinoma and association with the patients' prognosis].

Hui-zhong Zhang1, Jin-geng Liu, Yi-ping Wei, Cheng Wu, Yong-ke Cao, Mei Wang.   

Abstract

OBJECTIVE: To investigate the expressions of RhoC and osteopontin (OPN) protein in esophageal squamous carcinoma (ESC) and their association with the biological behavior of ESC.
METHODS: The expressions of RhoC and OPN protein were detected in 80 ESC cases by immunohistochemistry.
RESULTS: The positive expression rate of RhoC was 66.25% in these ESC cases. The rate was significantly higher in cases with lymph node metastasis than in those without (r(s)=-2.115, P<0.05), but RhoC expression was not associated with the tumor diameter, differentiation or TNM grade (P>0.05). The RhoC-positive patients had significantly shorter survival time than the negative patients (P<0.001). All the 80 ESC patients were positive for OPN expression, and OPN expression levels were correlated with the differentiation (chi(2)=10.766, P<0.05) and lymph node metastasis of the tumor (r(s)=-2.289, P<0.05), but not with the tumor diameter or TNM grade (P>0.05). Higher expression level of OPN was closely related to shorter survival time of the patients (P<0.05). A positive correlation was found between RhoC protein and OPN expressions (r(s)= 0.408, P<0.001) in these cases.
CONCLUSION: The expressions of RhoC and OPN protein are closely related to lymph node metastasis of ESC and the patients survival time, and therefore may serve the purpose of prognostic evaluation of ESC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17121713

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  2 in total

1.  RhoC, vascular endothelial growth factor and microvascular density in esophageal squamous cell carcinoma.

Authors:  Zhi-Hua Zhao; Yan Tian; Jian-Pin Yang; Jun Zhou; Kui-Sheng Chen
Journal:  World J Gastroenterol       Date:  2015-01-21       Impact factor: 5.742

Review 2.  Osteopontin as a biomarker for osteosarcoma therapy and prognosis.

Authors:  Xingwen Han; Wenji Wang; Jingjing He; Lei Jiang; Xun Li
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.